Buy Hydrea

Hydrea

What is Hydrea?

Hydrea is a brand-name medication that contains the active ingredient hydroxyurea. Hydroxyurea belongs to the class of antimetabolite agents and is used as an oncology support drug. In the United Kingdom, Hydrea is a prescription-only (POM) medication, regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is supplied as a 500 mg oral pill.

How Hydroxyurea Works in the Body

Hydroxyurea interferes with DNA synthesis by inhibiting the enzyme ribonucleotide reductase. This enzyme is essential for converting ribonucleotides to deoxyribonucleotides, the building blocks of DNA. By reducing the supply of deoxyribonucleotides, hydroxyurea:

• Slows cell division - rapidly proliferating cells, such as malignant leukocytes, are especially affected.
• Induces cellular stress - leading to apoptosis (programmed cell death) of abnormal cells.
• Modulates fetal haemoglobin - in sickle-cell disease this effect reduces sickling, though this use is considered off-label in oncology contexts.

The drug’s onset of action is typically within a few days, with peak myelosuppressive effects occurring after 2-3 weeks of therapy. Because hydroxyurea is taken orally, it is completely absorbed from the gastrointestinal tract, undergoing limited hepatic metabolism and being excreted primarily via the kidneys.

Conditions Treated with Hydrea

Hydroxyurea is licensed in the UK for the following oncology indications:

• Chronic myelogenous leukaemia (CML) - particularly in patients who are resistant or intolerant to first-line tyrosine-kinase inhibitors.
• Polycythaemia vera - to control elevated red-cell mass when phlebotomy alone is insufficient.
• Essential thrombocythaemia - for patients at high risk of thrombosis or those intolerant of other cytoreductive agents.

In each case, hydroxyurea is used to reduce abnormal blood cell proliferation and to maintain blood counts within safe limits.

Evidence-Based Off-Label Uses

Hydroxyurea has documented off-label benefits in sickle-cell disease, where it raises fetal haemoglobin levels and reduces painful crises. Clinical trials have demonstrated a reduction in hospitalisation rates, but this indication is not approved by the MHRA for oncology purposes. Off-label use should only be undertaken under specialist supervision, with careful risk-benefit assessment.

Who Should (and Should Not) Use Hydrea?

Ideal Patient Profile

• Adults with a confirmed diagnosis of CML, polycythaemia vera, or essential thrombocythaemia requiring cytoreductive therapy.
• Individuals with adequate renal and hepatic function to allow safe drug clearance.

Absolute Contra-indications

• Known hypersensitivity to hydroxyurea or any of the tablet’s excipients.
• Pregnant or breastfeeding women - hydroxyurea crosses the placenta and is excreted in breast milk, posing teratogenic risk.
• Patients with severe bone-marrow failure (e.g., aplastic anaemia) where further myelosuppression would be dangerous.

Relative Contra-indications

• Moderate renal impairment (creatinine clearance < 30 mL/min) - dose reduction may be needed.
• Hepatic dysfunction (Child-Pugh class B or C).
• Concomitant use of other strong myelosuppressive agents.

Special populations such as the elderly may require closer monitoring of blood counts due to a higher risk of cytopenias.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Mild nausea or gastrointestinal discomfort - usually transient.
• Skin hyperpigmentation - darkening of the hands, face, or nails.
• Hair thinning - reversible upon discontinuation.
• Low blood cell counts (leukopenia, anemia, thrombocytopenia) - the most frequently monitored adverse effect.

Serious Adverse Events

• Severe myelosuppression leading to infection or bleeding.
• Cutaneous ulceration or severe rash - may require drug cessation.
• Liver toxicity - evidenced by elevated transaminases.
• Teratogenicity - birth defects have been reported in animal studies and human case reports.

Drug Interactions

• Antiretrovirals (e.g., zidovudine) - additive bone-marrow suppression.
• Concurrent chemotherapy agents - may amplify cytotoxicity; dose adjustments are recommended.
• Phenytoin and other enzyme-inducing drugs - can increase hydroxyurea clearance, potentially lowering efficacy.

Food and Lifestyle Interactions

• Hydroxyurea can be taken with or without food; however, taking it with a full glass of water may reduce gastrointestinal irritation.
• Alcohol should be consumed in moderation, as both alcohol and hydroxyurea can affect liver function.
• Patients should avoid excessive sun exposure if they develop photosensitivity; protective clothing and sunscreen are advisable.

How to Take Hydrea

• Formulation: 500 mg film-coated tablets, to be swallowed whole with water.
• Standard dosing: Dosing is individualized by the prescribing physician. In many adult protocols, treatment begins with 500 mg once daily, with the dose titrated upward (often in 500 mg increments) based on blood-count response and tolerability.
• Special populations:
• Renal impairment: Lower starting doses and extended dosing intervals may be required.
• Elderly patients: Initiate at the lower end of the dosing range and monitor closely.
• Missed dose: Take the missed dose as soon as remembered on the same day; do not double the next dose.
• Overdose: Symptoms may include profound bone-marrow suppression, nausea, vomiting, and diarrhoea. Seek emergency medical assistance; supportive care and possible administration of growth-factor agents are typical.
• Discontinuation: Abrupt cessation may lead to rebound increases in blood cell counts; tapering the dose under medical supervision is recommended for long-term users.

Monitoring and Follow-Up

• Complete blood count (CBC) - weekly during the first month, then every 2-4 weeks once stable.
• Renal and hepatic function tests - at baseline and periodically during therapy.
• Pregnancy testing - for women of child-bearing potential before initiation and periodically thereafter.
• Clinical review: Patients should report symptoms such as fever, unexplained bruising, or persistent fatigue promptly.

Storage and Handling

• Store Hydrea tablets at room temperature (15-30 °C), protected from excess moisture and direct sunlight.
• Keep the container tightly closed and out of reach of children.
• Do not use tablets beyond the expiry date printed on the package.
• Dispose of unused tablets according to local pharmacy-take-back schemes or NHS guidelines for medication waste.

Medication-Specific Glossary

Myelosuppression

A reduction in the production of blood cells by the bone marrow, leading to low counts of white cells, red cells, or platelets.

Ribonucleotide Reductase

The enzyme targeted by hydroxyurea that converts ribonucleotides into deoxyribonucleotides, a critical step in DNA synthesis.

Cytoreductive Therapy

Treatment aimed at decreasing the number of abnormal blood cells, commonly used in myeloproliferative disorders.

Fetal Hemoglobin (HbF)

A form of hemoglobin normally present in newborns; hydroxyurea can increase HbF levels, which is therapeutically useful in sickle-cell disease.

Therapeutic Drug Monitoring (TDM)

The clinical practice of measuring drug concentrations in blood to optimise dosing and minimise toxicity (used for hydroxyurea in certain protocols).

Teratogenicity

The potential of a substance to cause birth defects when exposure occurs during pregnancy.

Medical Disclaimer

This article provides educational information about Hydrea and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.